Rapamycin used to be the gold standard longevity drug, but I stopped taking it after my biomarker data showed inconsistent results. Two years later, peer-reviewed research is finally catching up with that skepticism.
This is a reminder that even "consensus" compounds need rigorous individual testing. What works in model organisms doesn't always translate cleanly to human metabolic responses.
The longevity stack is still evolving—data beats hype every time.
This is a reminder that even "consensus" compounds need rigorous individual testing. What works in model organisms doesn't always translate cleanly to human metabolic responses.
The longevity stack is still evolving—data beats hype every time.